Scarica l'app Stockscreener
13.83
3.49%
-0.50
Dopo l'orario di chiusura:
13.86
0.03
+0.22%
Precedente Chiudi:
$14.33
Aprire:
$13.585
Volume 24 ore:
11,288
Relative Volume:
0.00
Capitalizzazione di mercato:
$2.37M
Reddito:
$8.97M
Utile/perdita netta:
$-15.21M
Rapporto P/E:
-0.1187
EPS:
-116.51
Flusso di cassa netto:
$-10.84M
1 W Prestazione:
-13.29%
1M Prestazione:
+4,575%
6M Prestazione:
+955.73%
1 anno Prestazione:
+233.25%
Intervallo 1D:
$13.50
$13.88
Intervallo di 1 settimana:
$13.21
$16.50
Portata 52W:
$0.19
$25.95
Nuwellis Inc Stock (NUWE) Company Profile
Nome
Nuwellis Inc
Settore
Industria
Telefono
952-345-4200
Indirizzo
12988 VALLEY VIEW ROAD, EDEN PRAIRIE
Confronta NUWE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUWE
Nuwellis Inc
|
13.83 | 2.37M | 8.97M | -15.21M | -10.84M | -116.51 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Nuwellis Inc Stock (NUWE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-29 | Iniziato | ROTH MKM | Buy |
Nuwellis Inc Borsa (NUWE) Ultime notizie
What analysts say about Nuwellis Inc. stockRecord-breaking gains - Autocar Professional
Nuwellis Regains Nasdaq Compliance After Delisting Risk - TipRanks
Nuwellis Regains Compliance to Trade on Nasdaq - MarketScreener
Nuwellis regains Nasdaq compliance as minimum bid price requirement met - Investing.com India
Nuwellis Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
Exclusive: Nuwellis CEO Reveals Personal Journey and Strategic Roadmap in Candid Investor Interview - Stock Titan
Nuwellis Regains Compliance with Nasdaq Listing Requirements - The Manila Times
Nuwellis regains Nasdaq compliance, avoids delisting hearing - Investing.com Australia
Nuwellis regains compliance with Nasdaq listing requirements - TipRanks
Nuwellis, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
Nuwellis Secures Future on Nasdaq as Stock Meets Critical Trading Requirements - Stock Titan
Nuwellis Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com
Is Nuwellis Inc. a good long term investmentFree AI-Backed Trading Signals - jammulinksnews.com
Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025 - The Manila Times
Nuwellis, Medical Fluid Management Leader, Sets Q2 2025 Earnings Call for August 12 - Stock Titan
Why Nuwellis Inc. stock attracts strong analyst attentionFree Consultation - Newser
What drives Nuwellis Inc. stock priceRapid-fire capital growth - jammulinksnews.com
Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant - MSN
Nuwellis Terminates REVERSE-HF Trial, Shifts Focus to Outpatient Heart Failure Care and Pediatric Markets - AInvest
Nuwellis Ends REVERSE-HF Trial to Focus on Growth Areas, Saves $4 Million - AInvest
Nuwellis ends clinical trial of its ultrafiltration tech for heart failure - MassDevice
Medical Stocks To Add to Your Watchlist – July 16th - Defense World
Nuwellis stock falls after company terminates REVERSE-HF clinical trial By Investing.com - Investing.com South Africa
Nuwellis stock falls after company terminates REVERSE-HF clinical trial - Investing.com
Nuwellis' New U.S. Patent and Market Implications: A Game-Changer in Fluid Management and a Long-Term Growth Catalyst for Investors - AInvest
Nuwellis terminates REVERSE-HF trial to focus on outpatient heart failure care - TipRanks
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care - The Manila Times
Nuwellis, Inc. Terminates REVERSE-HF Clinical Trial to Focus on Outpatient Market Opportunities - Nasdaq
Nuwellis Pivots from REVERSE-HF Trial: Strategic $4M Shift to Outpatient Heart Failure Care Revealed - Stock Titan
Nuwellis Plunges 11.29% After Patent Surge - AInvest
Biotech And Crypto Moves Set Off Trading Frenzy - Finimize
Nuwellis Surges to 137th in Market Rankings with $703 Million Trading Volume - AInvest
Nuwellis appoints John Erb as CEO - MSN
Nuwellis Secures Patent Leadership in CRRT: A Breakthrough in Fluid Management for Critical Care - AInvest
Medical Stocks To Add to Your WatchlistJuly 16th - MarketBeat
Nuwellis' Patent Breakthrough: Can Fluid Management Innovation Sustain Momentum? - AInvest
Nuwellis (NUWE) Stock Skyrockets On New Patent: What's Going On? - Benzinga
Markets Inch Up As Lower Oil Prices And Flat Inflation Stand Out - Finimize
Why Nuwellis Shares Are Exploding Today: A 200% Surge Explained - Investing.com
Nuwellis shares surge 26.71% intraday after receiving a new U.S. patent on fluid management. - AInvest
Why are NUWE Shares Surging in Premarket Trading Today? - Tokenist
NUWE Stock Soars: Will It Last? - timothysykes.com
Why Is Nuwellis Stock (NUWE) Up 140% Today? - TipRanks
Nuwellis Shares Skyrocket 127.7% on Patent Win, Earnings - AInvest
Nuwellis shares jump 10.16% premarket after securing new U.S. patent on fluid management. - AInvest
Nuwellis' Fluid Management Patent: A Strategic Leap Forward, But Can It Stem the Tide? - AInvest
Nuwellis Soars 63.16% on New Patent, Earnings - AInvest
Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering SystemRetail Mood Turns Buoyant - MenaFN
Nuwellis Inc Azioni (NUWE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):